Trial · NCT00308087
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With a Complete Response or Unconfirmed Complete Response at Week 8 With Confirmation at Week 12 | Rituximab | 1 | participants | ||
| Number of Participants With a Complete Response or Unconfirmed Complete Response at Week 8 With Confirmation at Week 12 | Rituximab + Sargramostim | 3 | participants | ||
| Summary of Treatment-Emergent Adverse Events (TEAE) | Rituximab | Patients with TEAEs | 34 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAE) | Rituximab + Sargramostim | Patients with TEAEs | 38 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAE) | Rituximab | Patients with Treatment-Related TEAEs | 21 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAE) | Rituximab + Sargramostim | Patients with Treatment-Related TEAEs | 37 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAE) | Rituximab | Number of Deaths | 0 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAE) | Rituximab + Sargramostim | Number of Deaths | 0 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAE) | Rituximab | Patients with Serious TEAEs | 4 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAE) | Rituximab + Sargramostim | Patients with Serious TEAEs | 4 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAE) | Rituximab | Patients with Study Discontinuation due to TEAEs | 0 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAE) | Rituximab + Sargramostim | Patients with Study Discontinuation due to TEAEs | 2 | participants | |
| Participant Summary of Best Response Across All Visits | Rituximab | Complete Response | 5 | participants | |
| Participant Summary of Best Response Across All Visits | Rituximab + Sargramostim | Complete Response | 5 | participants | |
| Participant Summary of Best Response Across All Visits | Rituximab | Complete Response Unconfirmed | 0 | participants | |
| Participant Summary of Best Response Across All Visits | Rituximab + Sargramostim | Complete Response Unconfirmed | 0 | participants | |
| Participant Summary of Best Response Across All Visits | Rituximab | Partial Response | 13 | participants | |
| Participant Summary of Best Response Across All Visits | Rituximab + Sargramostim | Partial Response | 14 | participants | |
| Participant Summary of Best Response Across All Visits | Rituximab | Stable Disease | 11 | participants | |
| Participant Summary of Best Response Across All Visits | Rituximab + Sargramostim | Stable Disease | 15 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00308087/results